12/3/2021  9:59:57 PM Chg. -0.59 Volume Bid- Ask- Market Capitalization Dividend Y. P/E Ratio
73.31USD -0.80% 491,036
Turnover: 35.92 mill.
-Bid Size: - -Ask Size: - 185.25 bill.USD 3.38% 26.29

Business description

Today’s Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through its prescription medicines, vaccines, biologic therapies and animal health products, the company works with customers and operate in more than 140 countries to deliver innovative health solutions. Merck also demonstrates its commitment to increasing access to healthcare through far-reaching policies, programs and partnerships.
 

Management board & Supervisory board

CEO
Robert M. Davis
Management board
Caroline Litchfield, Cristal N. Downing, Dave Williams, Dr. Dean Y. Li, Frank Clyburn, Jennifer Zachary, Julie L. Gerberding, Michael A. Klobuchar, Richard R. DeLuca Jr., Sanat Chattopadhyay, Steven C. Mizell
Supervisory board
Kenneth C. Frazier, Christine E. Seidman, M.D., Inge Thulin, Kathy J. Warden, Mary Ellen Coe, Pamela J. Craig, Patricia F. Russo, Paul B. Rothman, M.D., Peter C. Wendell, Risa J. Lavizzo-Mourey, M.D., Robert M. Davis, Stephen L. Mayo, Thomas H. Glocer
 

Company data

Name: Merck & Co. Inc.
Address: 2000 Galloping Hill Road,Kenilworth, New Jersey 07033, USA
Phone: +1-908-740-4000
Fax: -
E-mail: -
Internet: www.merck.com
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12/31
Free Float: 83.96%
IPO date: -

Investor relations

Name: Teri Loxam
IR phone: +1-908-740-1986
IR Fax: -
IR e-mail: investor_relations@merck.com

Company calendar

CW 6 | 2/3/2022 4th Quarter/Annual Report
CW 18 | 4/28/2022 Interim Report 1st Quarter/3 Months
CW 31 | 7/28/2022 Interim Report 2nd Quarter/6 Months
CW 44 | 10/27/2022 Interim Report 3rd Quarter/9 Months
 

Main Shareholders

Freefloat
 
83.96%
The Vanguard Group, Inc.
 
8.24%
BlackRock, Inc.
 
7.80%
Others
 
0.00%